RxDoctor Payments Data

Stephanie Pinard

Family · Statesboro, GANPI 1063062511

Payments from drug & device makers

$3,092in general payments, 2019–2025

Across 107 payments — averaging $28.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$306
  • Merck$303
  • AstraZeneca$303
  • Novartis$277
  • Johnson & Johnson$271
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$245
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$3,07199%
  • Education$201%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,092 in reported general payments places this provider in the 85th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$75,859
Medicare patients
415
Services billed
1,203

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan80$88,266
EliquisApixaban55$58,403
XareltoRivaroxaban18$16,468
FarxigaDapagliflozin Propanediol17$15,551
JardianceEmpagliflozin11$11,260
Ranolazine ErRanolazine26$1,788
Atorvastatin Calcium95$1,008
Metoprolol Succinate60$655
ClopidogrelClopidogrel Bisulfate52$570
Carvedilol83$549
Isosorbide Mononitrate ErIsosorbide Mononitrate45$537
Nitroglycerin51$453
Diltiazem 24hr Er (Cd)Diltiazem Hcl12$393
Metoprolol Tartrate48$240
Lisinopril23$189

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$277$88,26680 claims
PfizerEliquis$47$58,40355 claims
Johnson & JohnsonXarelto$271$16,46818 claims
AstraZenecaFarxiga$303$15,55117 claims
Boehringer IngelheimJardiance$12$11,26011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 6,258 family providers in Georgia.

Other family in Statesboro

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →